Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sandwich XELOX + 5-Fu Radiotherapy in Locally Advanced Rectal Cancer
ChiCTR-IIR-16007947Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Mar 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine, oxaliplatin and fluorouracil in rectal cancer (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Tumor response and Toxicity. Started Mar 2016; status: recruiting.
02
Drugs
capecitabineoxaliplatinfluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR-IIR-16007947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16007947.